Anti-agrin autoantibodies in myasthenia gravis

Neurology

Volumn 82, Issue 22, 2014, Pages 1976-1983

  Gasperi, Christiane ^a   Melms, Arthur ^d   Schoser, Benedikt ^b   Zhang, Yina ^a   Meltoranta, Julia ^a   Risson, Valerie ^e   Schaeffer, Laurent ^e   Schalke, Bertold ^c   Kröger, Stephan ^a  

^a UNIVERSITY OF MUNICH   (Germany)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^c UNIVERSITY OF REGENSBURG   (Germany)

^d UNIVERSITY OF TÜBINGEN   (Germany)

^e UNIVERSITÉ DE LYON   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AGRIN; AGRIN ANTIBODY; AUTOANTIBODY; CHOLINERGIC RECEPTOR ANTIBODY; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN 4 ANTIBODY; MUSCLE SPECIFIC TYROSINE KINASE ANTIBODY; UNCLASSIFIED DRUG;

ADULT; AGED; ANIMAL TISSUE; ANTIBODY DETECTION; ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEK293 CELL LINE; HUMAN; HUMAN CELL; LEG MUSCLE; MALE; MIDDLE AGED; MOUSE; MYASTHENIA GRAVIS; NEUROMUSCULAR SYNAPSE; NONHUMAN; PRIORITY JOURNAL; VERY ELDERLY;

ADULT; AGED, 80 AND OVER; AGRIN; ANIMALS; AUTOANTIBODIES; CELLS, CULTURED; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; LDL-RECEPTOR RELATED PROTEINS; MALE; MICE; MIDDLE AGED; MYASTHENIA GRAVIS; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTORS, CHOLINERGIC; RECEPTORS, NICOTINIC;

EID: 84903955213     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0000000000000478     Document Type: Article

References (27)

1. Farrugia ME, Vincent A. Autoimmune mediated neuromuscular junction defects. Curr Opin Neurol 2010;23: 489-495.
2. Newsom-Davis J. The emerging diversity of neuromuscular junction disorders. Acta Myol 2007;26: 5-10.
3. Lindstrom JM, Einarson BL, Lennon VA, Seybold ME. Pathological mechanisms in experimental autoimmune myasthenia gravis: I: immunogenicity of syngeneic muscle acetylcholine receptor and quantitative extraction of receptor and antibody-receptor complexes from muscles of rats with experimental autoimmune myasthenia gravis. J Exp Med 1976;144: 726-738.
4. Punga AR, Ruegg MA. Signaling and aging at the neuromuscular synapse: lessons learnt from neuromuscular diseases. Curr Opin Pharmacol 2012;12: 340-346.
5. Hoch W, McConville J, Helms S, Newsom-Davis J, Melms A, Vincent A. Auto-Antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies. Nat Med 2001;7: 365-368.
6. Diaz-Manera J, Rojas-Garcia R, Gallardo E, et al. Antibodies to AChR, MuSK and VGKC in a patient with myasthenia gravis and Morvan's syndrome. Nat Clin Pract Neurol 2007;3: 405-410.
7. Higuchi O, Hamuro J, Motomura M, Yamanashi Y. Autoantibodies to low-density lipoprotein receptor-related protein 4 in myasthenia gravis. Ann Neurol 2011;69: 418-422.
8. Pevzner A, Schoser B, Peters K, et al. Anti-LRP4 autoantibodies in AChR-And MuSK-Antibody-negative myasthenia gravis. J Neurol 2012;259: 427-435.
9. Zhang B, Tzartos JS, Belimezi M, et al. Autoantibodies to lipoprotein-related protein 4 in patients with double-seronegative myasthenia gravis. Arch Neurol 2012;69: 445-451.
10. Kim N, Stiegler AL, Cameron TO, et al. Lrp4 is a receptor for agrin and forms a complex with MuSK. Cell 2008;135: 334-342.
11. Zhang B, Luo S, Wang Q, Suzuki T, Xiong WC, Mei L. LRP4 serves as a coreceptor of agrin. Neuron 2008;60: 285-297.
12. Sanes JR, Lichtman JW. Development of the vertebrate neuromuscular junction. Ann Rev Neurosci 1999;22: 389-442.
13. Jaretzki A, Barohn RJ, Ernstoff RM, et al. Myasthenia gravis: recommendations for clinical research standards. Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America. Ann Thorac Surg 2000;70: 327-334.
14. Huze C, Bauche S, Richard P, et al. Identification of an agrin mutation that causes congenital myasthenia and affects synapse function. Am J Hum Genet 2009;85: 155-167.
15. Lin S, Maj M, Bezakova G, Magyar JP, Brenner HR, Ruegg MA. Muscle-wide secretion of a miniaturized form of neural agrin rescues focal neuromuscular innervation in agrin mutant mice. Proc Natl Acad Sci USA 2008;105: 11406-11411.
16. Schröder JE, Tegeler MR, Grosshans U, et al. Dystroglycan regulates structure, proliferation and differentiation of neuroepithelial cells in the developing vertebrate CNS. Dev Biol 2007;307: 62-78.
17. Tsen G, Halfter W, Kröger S, Cole GJ. Agrin is a heparan sulfate proteoglycan. J Biol Chem 1995;270: 3392-3399.
18. Eusebio A, Oliveri F, Barzaghi P, Ruegg MA. Expression of mouse agrin in normal, denervated and dystrophic muscle. Neuromuscul Disord 2003;13: 408-415.
19. Maselli RA, Fernandez JM, Arredondo J, et al. LG2 agrin mutation causing severe congenital myasthenic syndrome mimics functional characteristics of non-neural (z-) agrin. Hum Genet 2012;131: 1123-1135.
20. Bogdanik LP, Burgess RW. A valid mouse model of AGRINassociated congenital myasthenic syndrome. Hum Mol Genet 2011;20: 4617-4633.
21. Cossins J, Belaya K, Zoltowska K, et al. The search for new antigenic targets in myasthenia gravis. Ann NY Acad Sci 2012;1275: 123-128.
22. Ksiazek I, Burkhardt C, Lin S, et al. Synapse loss in cortex of agrin-deficient mice after genetic rescue of perinatal death. J Neurosci 2007;27: 7183-7195.
23. Moll J, Barzaghi P, Lin S, et al. An agrin minigene rescues dystrophic symptoms in a mouse model for congenital muscular dystrophy. Nature 2001;413: 302-307.
24. Vincent A, Leite MI, Farrugia ME, et al. Myasthenia gravis seronegative for acetylcholine receptor antibodies. Ann NY Acad Sci 2008;1132: 84-92.
25. Sanders DB, El-Salem K, Massey JM, McConville J, Vincent A. Clinical aspects of MuSK antibody positive seronegative MG. Neurology 2003;60: 1978-1980.
26. Zouvelou V, Kyriazi S, Rentzos M, et al. Double-seropositive myasthenia gravis. Muscle Nerve 2013;47: 465-466.
27. Romi F, Skeie GO, Gilhus NE, Aarli JA. Striational antibodies in myasthenia gravis: reactivity and possible clinical significance. Arch Neurol 2005;62: 442-446.